Back

Relationship of the duration of pulmonary vein isolation-refractory non-paroxysmal atrial fibrillation to the middle- to long-term outcome of the ExTRa Mapping-guided ablation.

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 5 - Atrial fibrillation and oral anticoagulation 2 Treatment ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Yusuke Okuyama

Uji Tokushukai Medical Center, Uji (Japan)

9 More presentations in this session

Presentation thumbnail
Sex differences in admission rates, use of anticoagulation, and outcomes for emergency department presentations of atrial fibrillation
Mr P. Daniele (Vancouver, CA)
Abstract Slides
Presentation thumbnail
Stroke and bleeding in low, intermediate and high risk patients with atrial fibrillation treated with edoxaban: Results of the ETNA-AF Europe registry
Professor J. De Groot (Amsterdam, NL)
Abstract
Presentation thumbnail
Vitamin k antagonists are associated with higher risk of osteoporotic fractures compared to non-vitamin k antagonist oral anticoagulants among atrial fibrillation patients: a nationwide cohort study.
Doctor C. Binding (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Label adherence of non-vitamin K antagonist oral anticoagulants and clinical outcomes in patients with atrial fibrillation: A nationwide study
Associate Professor H. Yu (Seoul, KR)
Abstract
Presentation thumbnail
Factors associated with inappropriate under-dosing of non-vitamin k antagonist oral anticoagulants (NOACs) by labelling criterion in patients with non-valvular atrial fibrillation in the UK
Doctor A. Ruigomez (Madrid, ES)
Abstract

Access the full session

Session thumbnail
Poster Session 5 - Atrial fibrillation and oral anticoagulation 2

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Interactive discussion and Q&A
thumbnail
Congress Session
Treatment strategies for atrial fibrillation in heart failure
thumbnail
Congress Session
EHRA Myths - Device-detected atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources